Regenerex Pharma (RGPX) Common Equity (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Common Equity data on file, last reported at -$4.7 million in Q3 2025.

• Common Equity for Q3 2025 came in at -$4.7 million, up 1.23% year-over-year; the trailing twelve-month figure through Sep 2025 was -$4.7 million (up 1.23% YoY), and the FY2025 annual result was -$4.2 million, down 2.32% from the prior year.
• Common Equity fell to -$4.7 million in Q3 2025 per RGPX's latest filing, from -$4.5 million in the prior quarter.
• Over five years, Common Equity peaked at -$835026.0 in Q1 2021 and troughed at -$5.1 million in Q4 2024.
• A 5-year average of -$2.6 million and a median of -$1.1 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity slumped 297.93% in 2024, then grew 1.23% in 2025.
• A 5-year view of Common Equity shows it stood at -$937168.0 in 2021, then fell by 14.88% to -$1.1 million in 2022, then sank by 260.01% to -$3.9 million in 2023, then tumbled by 30.38% to -$5.1 million in 2024, then advanced by 7.02% to -$4.7 million in 2025.
• Business Quant data shows RGPX's Common Equity at -$4.7 million in Q3 2025, -$4.5 million in Q2 2025, and -$4.2 million in Q1 2025.